Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics Revenues Increase, Losses Narrow Slightly in Q2 of 2004

NEW YORK, Jan. 28 (GenomeWeb News) - Celera Diagnostics reported increased revenues and slightly smaller losses for the fiscal year 2004 second quarter today, along with decreased R&D spending.

 

For the quarter ended Dec. 31, 2003, Celera Diagnostics, a joint venture of Applied
Biosystems and Celera Genomics, both units of Applera, reported revenues of $11 million, compared to $7.8 million for the same period a year ago.

 

The company's net loss for the quarter amounted to $9.3 million, compared to $9.9 million in the prior year quarter.

 

Celera Diagnostics spent $10.6 million for R&D and engineering during the quarter, compared to $12.6 million the year before.

 

 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.